This section of the website is for patients who have been prescribed Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex) in Ireland. Information for members of the general public can be found here.
Side effects reporting information is available at the bottom of this webpage.

This website has been commissioned by Ipsen Pharmaceuticals Ltd. and is intended for an Irish audience

All materials

Patient Booklet: Urinary incontinence in adults with Neurogenic Detrusor Overactivity

Adult Spasticity File
5 pages

This booklet is designed for use by healthcare professionals to support conversations with patients who are eligible for Dysport® treatment for Urinary incontinence with Neurogenic Detrusor Overactivity (NDO). It provides clear, accessible information about the condition, how Dysport® works, the treatment process, potential benefits and risks, and what patients can expect before, during, and after treatment.

DYS-IE-001068 | December 2025

Patient Booklet: Urinary incontinence in adults with Neurogenic Detrusor Overactivity
Explore more Adult Spasticity Patient Support

Explore more Adult Spasticity Patient Support

Browse

Reporting of side effects:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly to the HPRA. Reporting forms and information can be found at www.hpra.ie or email medsafety@hpra.ie. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256. By reporting side effects, you can help provide more information on the safety of this medicine.

To access relevant information about Adult Spasticity, please choose one of the following options:

I am a healthcare professional in Ireland

This section is for healthcare professionals only. Contains promotional information

I am a healthcare professional in Ireland

Adverse events should be reported.
Reporting forms and information can be found at www.hpra.ie or e-mail medsafety@hpra.ie.
The HPRA can also be contacted on +353 16764971. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256.

I am a patient

This section provides information to support patients that have been prescribed Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex).

I am a patient

I am a member of the general public

This section is for members of the general public.

I am a member of the general public

Reporting of side effects:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly to the HPRA. Reporting forms and information can be found at www.hpra.ie or email medsafety@hpra.ie. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256. By reporting side effects, you can help provide more information on the safety of this medicine.